XML 72 R27.htm IDEA: XBRL DOCUMENT v3.24.0.1
REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
Schedule of Changes in Contract Assets and Contract Liabilities
The following table summarized the changes in the contract asset and liability balances for the year ended December 31, 2023:
Dollars in thousandsTotal
Contract Asset
Contract asset, January 1, 2023
$10,122 
Transferred to trade receivable from contract asset included in beginning of the year contract asset(7,743)
Written off from beginning of the year contract asset due to Boston recall(2,379)
Contract asset, net of transferred to trade receivables on contracts during the period9,233 
Contract asset, December 31, 2023
$9,233 
Contract Liability
Contract liability, January 1, 2023
$16,127 
Recognition of revenue included in beginning of year contract liability(6,834)
Contract liability, net of revenue recognized on contracts during the period6,951 
Foreign currency translation8 
Contract liability, December 31, 2023
$16,252 
Schedule of Disaggregation of Revenue
The following table presents revenues disaggregated by the major sources of revenues for years-ended December 31, 2023, 2022 and 2021 (dollar amounts in thousands):
Year Ended December 31, 2023Year Ended December 31, 2022Year Ended December 31, 2021
Neurosurgery$818,101 $794,017 $802,959 
Instruments240,892 225,547 222,273 
Total Codman Specialty Surgical1,058,993 1,019,564 1,025,232 
Wound Reconstruction and Care(1)(2)
373,986 406,689 392,463 
Private Label108,594 131,413 124,753 
Total Tissue Technologies482,580 538,102 517,216 
Total revenue$1,541,573 $1,557,666 $1,542,448 
(1) See Note 4. Acquisitions and Divestitures, for details around the ACell and SIA acquisitions.
(2) On August 31, 2022, the Company completed the sale of its non-core traditional wound care ("TWC") business. See Note 4, Acquisitions and Divestitures